Gene synthesis, expression, purification and quality control in one service. Choose high-throughput, transient or stable cell line production according to your project.
Get a 2-Minute Estimate Talk to a PhD Expert
Clear, inclusive pricing
From $296 per antibody
Gene synthesis, codon optimization, expression, purification and QC included.
Production at every scale
From µg to kg
From multi-well plate screening to multi-liter production, with one partner throughout your project.
Ready to produce
Every antibody format
IgG, IgA, IgM, ScFv, Fab, VHH, ScFv-Fc, VHH-Fc, bispecifics, Fc-fusion. Your format, your backbone.
Complete our 2-minute project calculator to receive a personalized estimate for your recombinant antibody project.
Choose the right production method
From parallel candidate screening to long-term antibody supply, choose the production service that matches your quantity, timeline and project goals.
Generate hundreds of antibodies for exploratory projects, lead optimization and AI-driven discovery.
Produce purified antibodies for characterization and functional studies in as little as 3 weeks..
Establish a reliable production cell line for long-term antibody supply.
| High-Throughput | Transient Expression | Stable Cell Line | |
|---|---|---|---|
| Gene integration | Transient — no genome integration | Transient — no genome integration | Permanent — stably integrated |
| Scale per antibody | µg – mg Multi-well plate |
mg – grams 30 mL to multi-liter bioreactors |
grams Fed-batches |
| Throughput | 100+ antibodies in parallel | 1 to dozens antibodies | Single clone per cell line |
| Turnaround | From 15 days | From 15 days | From 4 months |
| Typical use | Rapid variant screening Lead candidate selection AI model training datasets Antibody optimization panels |
Lead production & characterization Antibody engineering validation Preclinical in vitro studies |
Preclinical studies Regulatory submissions (IND/IVD) Long-term consistent supply |
| Development stage | Early discovery | Lead optimization | Preclinical |
| Royalties | 100% royalty-free | 100% royalty-free | 100% royalty-free |
| Next stage | Scale up to Transient Expression | Scale up to transient expression in bioreactors or Stable Cell line development |
Transfer to partner CDMO for GMP manufacturing |
Custom process
A simple, transparent workflow from project definition to purified antibody delivery.
Project definition
Define your production requirements
Format, quantity, timeline, application and quality requirements reviewed with your dedicated PhD expert.
Production platform
Choose your production method
High-throughput expression, transient production or stable cell line development, according to your project stage and required scale.
Gene synthesis & vector
Customize your sequence and expression construct
Codon optimization, gene synthesis and cloning into the selected expression vector.
Production & purification
Choose your purification level
Default: Affinity chromatography using Protein A/G.
Quality control
Choose your QC level
Default: Quantification by UV280, reducing and non-reducing SDS-PAGE, and purity evaluation.
Proof of monoclonality by VIPS™ for stable cell lines.
Delivery
Receive your purified antibodies and complete project documentation
Detailed report and purified antibody samples in PBS, pH 7.5, azide-free and sterilized by membrane filtration.
Stable cell line included with the stable cell line development service.
Our proprietary XtenCHO® Race platform is engineered for high-productivity mammalian transient expression. It produces more antibody from the same culture volume without feeding strategies or chemical boosters.
XtenCHO® Race has achieved up to 1.8 g/L in mammalian transient expression.
Comparison of the production yield of 10 therapeutic antibodies with XtenCHO® Race vs Market Leader
XtenCHO® Race Case Reports
Explore how XtenCHO® Race performs across high-throughput candidate screening and mid-scale production for preclinical development.
High-throughput expression service
A mid-size Canadian biotech developing a therapeutic antibody for colorectal cancer needed to compare the production yields of 18 in-house antibody sequences. XtenCHO® Race small-scale expression enabled rapid yield comparison without using internal production resources.
Result: faster candidate selection with comparable production data across all 18 antibody variants.
Transient expression service
A pharmaceutical company developing a recombinant antibody for rheumatoid arthritis needed to assess yield robustness during a 200 mL scale-up before advancing the lead candidate toward preclinical validation.
Result: preclinical-grade material meeting defined yield, endotoxin and purity requirements for the next development stage.
Want to see whether XtenCHO® Race fits your antibody project?
Discuss your sequence, scale and quality requirements with a PhD expert.
Why ProteoGenix
Fully customizable
Select the vector, expression strategy, purification, formulation and characterization required for your study.
Scalable solutions
From µg to kg, we support your project from early discovery to industrial-scale production.
Extensive antibody formats
IgG, IgA, IgM, IgE, Fab, scFv, VHH, bispecifics, Fc-fusion proteins. We can produce the format you require.
Competitive pricing
One of the most cost-effective price on the market for antibody production, plus royalty-free stable cell line generation.
Engineer your antibodies faster than ever
Thanks to the unique combination of our high-performance antibody production platform and AI-driven engineering solutions, you can optimize your antibodies faster than ever before!
Dedicated PhD support
A scientific project manager helps define the production route and follows the project through delivery.
Ramon Llull University, Spain
Nathanaël Rakotoarinoro, PhD, Postdoctoral researcher
“I have collaborated on several occasions with ProteoGenix for the production of recombinant antibodies. I greatly appreciated the responsiveness of the Account Manager, as well as their ability to identify the most appropriate solutions based on our needs and requirements. Overall, ProteoGenix’s services have often exceeded those of market leaders, and I have always been highly satisfied with the quality and quantity of the delivered products. This applies both to the antibodies produced and to the corresponding plasmids re-cloned into our in-house vectors, with a 100% success rate so far.”
LETI Pharma, Spain
Jose Luis Donoso Muñoz, Project Manager
“It was a real pleasure working with the Proteogenix team. Everything went very smoothly, the coordination was close and efficient, and they were always quick to respond to any doubts or questions. We truly appreciated how attentive they were throughout the entire process; at all times, we felt the communication was fluid and proactive. The delivery timelines were perfectly met, which made the collaboration even more seamless. I’d be happy to work together with them again in the future.”
University Hospital Basel, Switzerland
Nicolas Kramer, PhD, Postdoctoral researcher
“Working with ProteoGenix antibody production team has been an outstanding experience. The entire process was smooth, professional, and scientifically rigorous from start to finish. Communication was clear, timelines were met, and the final antibodies were delivered with a great amount of validation data. I truly appreciated ProteoGenix technical expertise and reliability, and I would gladly collaborate again in the future.”
